{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:58:58Z","timestamp":1792025938254,"version":"4.4.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sorrento Therapeutics, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The exploration and identification of safe and effective vaccines for the SARS-CoV-2 pandemic have captured the world's attention and remains an ongoing issue due to concerns of balancing protection against emerging variants of concern while also generating long-lasting immunity. Here, we report the synthesis of a novel messenger ribonucleic acid encoding the spike protein in a lipid nanoparticle formulation (STI-7264) that generates robust humoral and cellular immunity following immunization of C57Bl6 mice. In an effort to improve immunity, a clinically focused lymphatic drug delivery device (MuVaxx) was engineered to modulate immune cells at the injection site (epidermis and dermis) and draining lymph node (LN) and tested to measure adaptive immunity. Using MuVaxx, immune responses were elicited and maintained at a 10-fold dose reduction compared to traditional intramuscular (IM) administration as measured by anti-spike antibodies, cytokine-producing CD8 T cells, neutralizing antibodies against the Washington (wild type) strain and South African (Beta) variants, and LN-resident spike-specific memory B cells. Remarkably, a 4-fold-elevated T cell response was observed in MuVaxx-administered vaccination compared to that of IM-administered vaccination. Thus, these data support further investigation into STI-7264 and lymphatic-mediated delivery using MuVaxx for SARS-CoV-2 and VoC vaccines.<\/jats:p>","DOI":"10.1093\/jmcb\/mjac041","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T23:17:34Z","timestamp":1657322254000},"source":"Crossref","is-referenced-by-count":5,"title":["Delivering an mRNA vaccine using a lymphatic drug delivery device improves humoral and cellular immunity against SARS-CoV-2"],"prefix":"10.1093","volume":"14","author":[{"given":"Runqiang","family":"Chen","sequence":"first","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahba","family":"Khorsandzadeh","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"},{"name":"Sofusa, a Division of Sorrento Therapeutics , Atlanta, GA 30350 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Smith","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"},{"name":"Sofusa, a Division of Sorrento Therapeutics , Atlanta, GA 30350 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namir","family":"Shaabani","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidong","family":"Hu","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Lyu","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-lin","family":"Lim","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Sun","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Ji","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Cooley","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"},{"name":"Sofusa, a Division of Sorrento Therapeutics , Atlanta, GA 30350 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Ross","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"},{"name":"Sofusa, a Division of Sorrento Therapeutics , Atlanta, GA 30350 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Francis","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics, Inc. , San Diego, CA 92121 , USA"},{"name":"Sofusa, a Division of Sorrento Therapeutics , Atlanta, GA 30350 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"2022122008595497300_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1323-z","article-title":"Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis","volume":"19","author":"Aldrich","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"2022122008595497300_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2015.11.019","article-title":"Microneedle patches for vaccination in developing countries","volume":"240","author":"Arya","year":"2016","journal-title":"J. Control. Release"},{"key":"2022122008595497300_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"2022122008595497300_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1084\/jem.165.1.64","article-title":"IgG2a restriction of murine antibodies elicited by viral infections","volume":"165","author":"Coutelier","year":"1987","journal-title":"J. Exp. Med."},{"key":"2022122008595497300_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aay3575","article-title":"Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy","volume":"12","author":"Francis","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"2022122008595497300_bib7","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jama.1967.03130250057008","article-title":"Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines","volume":"202","author":"Fulginiti","year":"1967","journal-title":"JAMA"},{"key":"2022122008595497300_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"2022122008595497300_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.immuni.2014.12.024","article-title":"Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens","volume":"42","author":"Gerner","year":"2015","journal-title":"Immunity"},{"key":"2022122008595497300_bib10","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"2022122008595497300_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2471\/BLT.10.079426","article-title":"Intradermal delivery of vaccines: potential benefits and current challenges","volume":"89","author":"Hickling","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"2022122008595497300_bib12","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2\u2014preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2022122008595497300_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"2022122008595497300_bib14","first-page":"77","article-title":"Delivery systems for intradermal vaccination","volume":"351","author":"Kim","year":"2011","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2022122008595497300_bib15","doi-asserted-by":"crossref","first-page":"8332","DOI":"10.7150\/thno.35280","article-title":"Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy","volume":"9","author":"Kwon","year":"2019","journal-title":"Theranostics"},{"key":"2022122008595497300_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-021-00657-1","article-title":"The germinal centre B cell response to SARS-CoV-2","volume":"22","author":"Laidlaw","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"2022122008595497300_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"2022122008595497300_bib17","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-CoV-2 mRNA vaccines foster potent antigen-specific Germinal center responses associated with neutralizing antibody generation","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"key":"2022122008595497300_bib18","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jmcb\/mjaa070","article-title":"The development of neutralizing antibodies against SARS-CoV-2 and their common features","volume":"12","author":"Liu","year":"2021","journal-title":"J. Mol. Cell Biol."},{"key":"2022122008595497300_bib19","doi-asserted-by":"crossref","first-page":"e105114","DOI":"10.15252\/embj.2020105114","article-title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells","volume":"39","author":"Lukassen","year":"2020","journal-title":"EMBO J."},{"key":"2022122008595497300_bib20","doi-asserted-by":"crossref","first-page":"e229317","DOI":"10.1001\/jamanetworkopen.2022.9317","article-title":"Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis","volume":"5","author":"Madewell","year":"2022","journal-title":"JAMA Network Open"},{"key":"2022122008595497300_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"key":"2022122008595497300_bib22","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1038\/s41467-018-05772-7","article-title":"Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes","volume":"9","author":"Moran","year":"2018","journal-title":"Nat. Commun."},{"key":"2022122008595497300_bib23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"2022122008595497300_bib24","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2021.01.055","article-title":"Vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"39","author":"Munoz","year":"2021","journal-title":"Vaccine"},{"key":"2022122008595497300_bib25","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.vaccine.2016.02.063","article-title":"Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection","volume":"34","author":"Ng","year":"2016","journal-title":"Vaccine"},{"key":"2022122008595497300_bib26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.addr.2011.05.018","article-title":"The role of the lymphatic system in vaccine trafficking and immune response","volume":"63","author":"Pal","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2022122008595497300_bib27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2007.02.011","article-title":"The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles","volume":"26","author":"Pape","year":"2007","journal-title":"Immunity"},{"key":"2022122008595497300_bib28","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine\u2013induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"key":"2022122008595497300_bib29","article-title":"Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors","author":"Perreault","year":"2020","journal-title":"bioRxiv"},{"key":"2022122008595497300_bib30","article-title":"Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence","author":"Puranik","journal-title":"medRxiv"},{"key":"2022122008595497300_bib31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/icb.2010.39","article-title":"Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy","volume":"88","author":"Romani","year":"2010","journal-title":"Immunol. Cell Biol."},{"key":"2022122008595497300_bib32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/eji.201041225","article-title":"Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection","volume":"42","author":"Schmitz","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"2022122008595497300_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41578-019-0110-7","article-title":"Material design for lymph node drug delivery","volume":"4","author":"Schudel","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"2022122008595497300_bib34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"2022122008595497300_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1087-0024.2000.00001.x","article-title":"Structure, function, and molecular control of the skin lymphatic system","volume":"5","author":"Skobe","year":"2000","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"2022122008595497300_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(01)00150-8","article-title":"The physiology of the lymphatic system","volume":"50","author":"Swartz","year":"2001","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"2022122008595497300_bib37","doi-asserted-by":"crossref","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep."},{"key":"2022122008595497300_bib38","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.4049\/jimmunol.1103545","article-title":"Impaired humoral immunity and tolerance in K14-VEGFR-3-Ig mice that lack dermal lymphatic drainage","volume":"189","author":"Thomas","year":"2012","journal-title":"J. Immunol."},{"key":"2022122008595497300_bib39","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour-targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"2022122008595497300_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"2022122008595497300_bib41","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1021\/nl504829f","article-title":"Nanotopography facilitates in vivo transdermal delivery of high molecular weight therapeutics through an integrin-dependent mechanism","volume":"15","author":"Walsh","year":"2015","journal-title":"Nano Lett."},{"key":"2022122008595497300_bib42","doi-asserted-by":"crossref","first-page":"eabd2071","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf","year":"2020","journal-title":"Sci. Immunol."},{"key":"2022122008595497300_bib43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri2496","article-title":"Migration, maintenance and recall of memory T cells in peripheral tissues","volume":"9","author":"Woodland","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"2022122008595497300_bib44","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"}],"container-title":["Journal of Molecular Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jmcb\/advance-article-pdf\/doi\/10.1093\/jmcb\/mjac041\/44686042\/mjac041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jmcb\/article-pdf\/14\/6\/mjac041\/48247060\/mjac041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jmcb\/article-pdf\/14\/6\/mjac041\/48247060\/mjac041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T09:01:25Z","timestamp":1671526885000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jmcb\/article\/doi\/10.1093\/jmcb\/mjac041\/6634240"}},"subtitle":[],"editor":[{"given":"Bing","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jmcb\/mjac041","relation":{},"ISSN":["1674-2788","1759-4685"],"issn-type":[{"value":"1674-2788","type":"print"},{"value":"1759-4685","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6]]},"published":{"date-parts":[[2022,6]]},"article-number":"mjac041"}}